Guided Therapeutics (GTHP) Return on Capital Employed Growth (1y) (2013 - 2025)
Guided Therapeutics (GTHP) Return on Capital Employed Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.85 Bn | 176.55 Bn | 6.27 Bn | -81.00 |
| 2 | Stryker | 128.90 Bn | 126.02 Bn | 3.81 Bn | -1,390.00 |
| 3 | Medtronic | 108.55 Bn | 99.33 Bn | 6.41 Bn | 39.00 |
| 4 | Boston Scientific | 68.56 Bn | 67.10 Bn | 3.61 Bn | 141.00 |
| 5 | Edwards Lifesciences | 48.24 Bn | 44.57 Bn | 1.29 Bn | -110.00 |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 658.00 |
| 7 | GE HealthCare Technologies | 28.15 Bn | 25.87 Bn | 1.98 Bn | -3,185.00 |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.75 Bn | 21.63 Bn | 2.07 Bn | 125.00 |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | -61.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -61.00 |
| Sep 30, 2025 | -356.00 |
| Jun 30, 2025 | -678.00 |
| Mar 31, 2025 | -3,325.00 |
| Dec 31, 2024 | -7,027.00 |
| Sep 30, 2024 | -10,086.00 |
| Jun 30, 2024 | -14,649.00 |
| Mar 31, 2024 | -34,797.00 |
| Dec 31, 2023 | -15,262.00 |
| Sep 30, 2023 | 2,936.00 |
| Jun 30, 2023 | 14,501.00 |
| Mar 31, 2023 | 36,926.00 |
| Dec 31, 2022 | 20,580.00 |
| Sep 30, 2022 | 4,654.00 |
| Jun 30, 2022 | -264.00 |
| Mar 31, 2022 | 3,559.00 |
| Dec 31, 2021 | 4,688.00 |
| Sep 30, 2021 | 5,517.00 |
| Jun 30, 2021 | 4,071.00 |
| Mar 31, 2021 | 1,124.00 |